4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Scott Bizily Sells 1,750 Shares

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,750 shares of the company’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $25.74, for a total transaction of $45,045.00. Following the sale, the insider now directly owns 1,737 shares of the company’s stock, valued at $44,710.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Scott Bizily also recently made the following trade(s):

• On Monday, April 1st, Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $31.78, for a total transaction of $259,102.34.
• On Wednesday, March 27th, Scott Bizily sold 5,833 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $35.04, for a total transaction of $204,388.32.
• On Monday, March 18th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $31.27, for a total transaction of $54,722.50.
• On Tuesday, February 27th, Scott Bizily sold 1,909 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $57,270.00.
• On Friday, February 16th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $27.67, for a total transaction of $48,422.50.
• On Thursday, February 8th, Scott Bizily sold 6,244 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $27.50, for a total transaction of $171,710.00.

4D Molecular Therapeutics Stock Performance

Shares of NASDAQ:FDMT traded down $0.52 on Thursday, reaching $24.78. The company’s stock had a trading volume of 417,554 shares, compared to its average volume of 1,078,209. 4D Molecular Therapeutics, Inc. has a 52-week low of $9.44 and a 52-week high of $36.25. The company has a market cap of $1.27 billion, a P/E ratio of -9.32 and a beta of 2.87. The company has a 50-day simple moving average of $28.97 and a 200 day simple moving average of $20.13.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.09). 4D Molecular Therapeutics had a negative return on equity of 34.14% and a negative net margin of 436.30%. The business had revenue of ($0.02) million during the quarter, compared to analysts’ expectations of $4.67 million. On average, equities research analysts forecast that 4D Molecular Therapeutics, Inc. will post -3.03 EPS for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of large investors have recently made changes to their positions in the company. RA Capital Management L.P. boosted its stake in shares of 4D Molecular Therapeutics by 35.6% during the 3rd quarter. RA Capital Management L.P. now owns 4,163,211 shares of the company’s stock worth $52,998,000 after purchasing an additional 1,093,680 shares during the period. BlackRock Inc. boosted its stake in shares of 4D Molecular Therapeutics by 14.3% during the 2nd quarter. BlackRock Inc. now owns 2,914,430 shares of the company’s stock worth $52,664,000 after purchasing an additional 363,695 shares during the period. State Street Corp boosted its stake in shares of 4D Molecular Therapeutics by 0.4% during the 2nd quarter. State Street Corp now owns 2,050,430 shares of the company’s stock worth $37,051,000 after purchasing an additional 8,241 shares during the period. Novo Holdings A S boosted its stake in shares of 4D Molecular Therapeutics by 25.0% during the 4th quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock worth $30,390,000 after purchasing an additional 300,000 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of 4D Molecular Therapeutics by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,290,941 shares of the company’s stock worth $19,519,000 after purchasing an additional 7,858 shares during the period. 99.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on FDMT. BMO Capital Markets reduced their price objective on shares of 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating for the company in a research note on Monday, April 1st. HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, March 1st. Jefferies Financial Group lifted their price target on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the company a “buy” rating in a report on Monday, April 1st. The Goldman Sachs Group reiterated a “buy” rating and issued a $81.00 price target on shares of 4D Molecular Therapeutics in a report on Wednesday, February 7th. Finally, Barclays assumed coverage on shares of 4D Molecular Therapeutics in a report on Monday. They issued an “overweight” rating on the stock. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $44.22.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.